Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
OBI Pharma, Inc. (4174.TWO)
TWD29.45
+1.05 (+3.70%)
TW TWO Healthcare Biotechnology
Address
No. 3, Park Street 115
Taipei, TW
Taipei, TW
CEO
Heidi Wang
Website
obipharma.com
IPO
2012-12-12
ISIN TW0004174008
Description
OBI Pharma, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing cutting-edge therapies for critical medical needs, specifically in the field of cancer, with operations spanning Taiwan and international markets. The company's extensive product pipeline features numerous advanced treatment candidates. These include Adagloxad Simolenin (OBI-822), an active immunity drug for breast cancer designed to stimulate antibody production against the tumor carbohydrate antigen Globo H; OBI-833, an immunity-boosting anti-cancer agent targeting lung cancer; OBI-866 SSEA-4, another active immune-oncology medication; and OBI-888, a passive immunotherapy monoclonal antibody also developed to confront Globo H. Additionally, their portfolio contains OBI-999, an antibody-drug conjugate; OBI-3424, a small-molecule chemotherapy prodrug; OBI-858, a botulinum toxin; and other investigational drugs such as OBI-898 and OBI-998. Founded in 2002, the enterprise is headquartered in Taipei, Taiwan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
TWD29.45
+1.05 (+3.70%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
560.5K
Beta
0.08
Float Shares
86.78M
Free Float %
66.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.62% | -5.00% | -14.89% | -22.54% | +18.10% | -40.19% | -14.10% | -61.18% | -69.33% | -92.39% | -72.75% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
29.45
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-1.40
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-6.6% Q1'26: -61.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-57.8% Q1'26: +14.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-3,721.1% Q1'26: -8,777.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-3,702.6% Q1'26: -8,166.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-105.6% Q1'26: -88.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-43.7% ★ Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.27× Q1'26: -0.28× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2019 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
Dec 2031 1 Rev. Ana. 1 EPS Ana. |
Dec 2032 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 32.67M (-100.0%)
|
92.42M
est: 1.00M (+9,142.2%)
|
872.0K
est: 1.00M (-12.8%)
|
4.71M
est: 9.00M (-47.7%)
|
41.55M
est: 11.00M (+277.7%)
|
62.68M
est: 51.00M (+22.9%)
|
58.58M
est: 3.05B (-98.1%)
|
68.74M
68.74M – 68.74M
-97.7% YoY
|
80.66M
80.66M – 80.66M
+17.4% YoY
|
1.00M
1.00M – 1.00M
-98.8% YoY
|
111.09M
111.09M – 111.09M
+11,008.5% YoY
|
130.36M
130.36M – 130.36M
+17.4% YoY
|
9.00M
9.00M – 9.00M
-93.1% YoY
|
11.00M
11.00M – 11.00M
+22.2% YoY
|
| EBITDA |
-906.38M
est: -32.67M (-2,674.6%)
|
-1.06B
est: -1.00M (-106,098.3%)
|
-1.50B
est: -1.00M (-150,153.7%)
|
-1.67B
est: -9.00M (-18,416.6%)
|
-1.02B
est: -11.00M (-9,160.6%)
|
-2.26B
est: -51.00M (-4,337.8%)
|
-1.94B
est: -3.05B (+36.4%)
|
-68.74M
-68.74M – -68.74M
+97.7% YoY
|
-80.66M
-80.66M – -80.66M
-17.4% YoY
|
-1.00M
-1.00M – -1.00M
+98.8% YoY
|
-111.09M
-111.09M – -111.09M
-11,008.5% YoY
|
-130.36M
-130.36M – -130.36M
-17.4% YoY
|
-9.00M
-9.00M – -9.00M
+93.1% YoY
|
-11.00M
-11.00M – -11.00M
-22.2% YoY
|
| EBIT |
-939.81M
est: -32.67M (-2,777.0%)
|
-1.11B
est: -1.00M (-110,641.1%)
|
-1.72B
est: -1.00M (-171,544.0%)
|
-1.91B
est: -9.00M (-21,156.7%)
|
-1.27B
est: -11.00M (-11,423.8%)
|
-2.49B
est: -51.00M (-4,773.6%)
|
-2.17B
est: -3.05B (+28.9%)
|
-68.74M
-68.74M – -68.74M
+97.7% YoY
|
-80.66M
-80.66M – -80.66M
-17.4% YoY
|
-1.00M
-1.00M – -1.00M
+98.8% YoY
|
-111.09M
-111.09M – -111.09M
-11,008.5% YoY
|
-130.36M
-130.36M – -130.36M
-17.4% YoY
|
-9.00M
-9.00M – -9.00M
+93.1% YoY
|
-11.00M
-11.00M – -11.00M
-22.2% YoY
|
| Net Income |
-941.34M
est: -1.26B (+25.1%)
|
-1.11B
est: -1.36B (+18.6%)
|
-1.44B
est: -1.54B (+6.7%)
|
-1.90B
est: -1.61B (-17.7%)
|
-1.05B
est: -1.89B (+44.6%)
|
-2.31B
est: -1.28B (-80.3%)
|
-2.05B
est: 681.20M (-401.4%)
|
-476.74M
-476.74M – -476.74M
-170.0% YoY
|
-588.13M
-588.13M – -588.13M
-23.4% YoY
|
-434.20M
-434.20M – -434.20M
+26.2% YoY
|
-501.66M
-501.66M – -501.66M
-15.5% YoY
|
-431.61M
-431.61M – -431.61M
+14.0% YoY
|
-454.28M
-454.28M – -454.28M
-5.3% YoY
|
-531.41M
-531.41M – -531.41M
-17.0% YoY
|
| SGA |
415.06M
est: 611.14M (-32.1%)
|
345.41M
est: 18.71M (+1,746.3%)
|
267.54M
est: 18.71M (+1,330.1%)
|
309.76M
est: 168.37M (+84.0%)
|
319.28M
est: 205.79M (+55.1%)
|
326.78M
est: 959.44M (-65.9%)
|
151.29M
est: 57.40B (-99.7%)
|
1.29B
1.29B – 1.29B
-97.7% YoY
|
1.52B
1.52B – 1.52B
+17.4% YoY
|
18.81M
18.81M – 18.81M
-98.8% YoY
|
2.09B
2.09B – 2.09B
+11,008.5% YoY
|
2.45B
2.45B – 2.45B
+17.4% YoY
|
169.31M
169.31M – 169.31M
-93.1% YoY
|
206.94M
206.94M – 206.94M
+22.2% YoY
|
| EPS |
-11.10
est: -5.38 (-106.4%)
|
-12.78
est: -5.84 (-118.9%)
|
-14.86
est: -6.60 (-125.0%)
|
-17.10
est: -6.91 (-147.5%)
|
-9.14
est: -8.08 (-13.1%)
|
-19.78
est: -19.48 (-1.5%)
|
-31.22
est: 10.36 (-401.4%)
|
-7.25
-7.25 – -7.25
-170.0% YoY
|
-8.94
-8.94 – -8.94
-23.4% YoY
|
-6.60
-6.60 – -6.60
+26.2% YoY
|
-7.63
-7.63 – -7.63
-15.5% YoY
|
-6.56
-6.56 – -6.56
+14.0% YoY
|
-6.91
-6.91 – -6.91
-5.3% YoY
|
-8.08
-8.08 – -8.08
-17.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-2.43B
OE per share TTM
-18.90
Owner's Yield
-326.90%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
2,142.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 17 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 8.5K | 0.56% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 307.9K | 0.06% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 21.2K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 9.4K | 0.48% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 58.9K | 0.39% |
| 6 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.04M | 0.06% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 53.0K | 0.28% |
| 8 | Vanguard ESG International Stock ETF VSGX | 0.00% | 13.9K | 0.10% |
| 9 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.14M | 0.05% |
| 10 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 1.7K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-83.4K
Shares Outstanding
131.48M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Heidi Wang | Chief Executive Officer & Director | 10M | — |
| Ya-Chi Chen | Interim CEO & CSO | 6M | female |
| Colin Kao | Chief Operating Officer & Finance Director | 4M | male |
| Chun-Hung Chou | Vice President of Chemical Pharmacy and R&D Office | — | male |
| Ruo Chen Zhuang | Accounting Supervisor | — | — |
| Steven Innaimo | Interim COO & VP of Clinical Operations of OBI Pharma USA, Inc. | — | male |
| Wade Liu | Head of Global Manufacturing & Supply Chain | — | male |
| Po-Jen Chang | Director of Human Resources & Administration | — | male |
| Dong Xu | Chief Medical Officer of OBI Pharma USA, Inc. | — | — |
| Kevin Poulos | Chief Business Officer of OBI Pharma USA, Inc. | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4174.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
